Kymera Therapeutics
KYMR
127 hedge funds and large institutions have $1.15B invested in Kymera Therapeutics in 2022 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 41 increasing their positions, 33 reducing their positions, and 10 closing their positions.
270% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 10
34% more call options, than puts
Call options by funds: $2.67M | Put options by funds: $1.99M
27% more funds holding
Funds holding: 100 → 127 (+27)
24% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 33
18% more capital invested
Capital invested by funds: $974M → $1.15B (+$177M)
1.02% more ownership
Funds ownership: 95.55% → 96.56% (+1%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$24M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$21M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$14.6M |
| 4 |
AG
Artal Group
Luxembourg
|
+$13.2M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$12.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$42.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$29.7M |
| 3 |
State Street
Boston,
Massachusetts
|
-$21.9M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$4.32M |
| 5 |
Morgan Stanley
New York
|
-$4.25M |
KYMR Hedge Fund Activity: Q3 2022 in Review
127 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q3 2022, worth a combined $1.15B — up 18% from $974M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new KYMR positions and 10 closed out — a net gain of 27 holders — while 41 added to existing stakes and 33 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $24M. The largest seller was Wellington Management Group, cutting an estimated $42.8M.
- 127 institutional investors held Kymera Therapeutics (KYMR) as of Q3 2022, up from 100 in Q2 2022.
- Funds reported $1.15B of Kymera Therapeutics stock for Q3 2022, up 18% quarter-over-quarter.
- 37 funds opened new Kymera Therapeutics positions in Q3 2022 and 10 closed out, a net change of +27 holders.
- The largest Kymera Therapeutics buyer in Q3 2022 was Avoro Capital Advisors, an estimated $24M added.
- The largest Kymera Therapeutics seller in Q3 2022 was Wellington Management Group, an estimated $42.8M sold.
Based on aggregated 13F filings for Q3 2022.